Michael J. McElhaugh - Feb 4, 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Signature
/s/ David C. Hastings as attorney-in-fact for Michael J. McElhaugh
Stock symbol
ABUS
Transactions as of
Feb 4, 2025
Transactions value $
-$78,103
Form type
4
Date filed
2/5/2025, 04:02 PM
Previous filing
Feb 5, 2024
Next filing
Feb 19, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABUS Common Shares Sale -$78.1K -23.8K -1.58% $3.28 1.48M Feb 4, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 3, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units.